Quale sarebbe il prezzo per Jiangsu Recbio Technology Co., Ltd. (2179)

Il prezzo per Jiangsu Recbio Technology Co., Ltd. (2179) è $0.63963115

Qual è la capitalizzazione di mercato per Jiangsu Recbio Technology Co., Ltd. (2179)

La capitalizzazione di mercato per Jiangsu Recbio Technology Co., Ltd. (2179) è $339.16M

Jiangsu Recbio Technology Co., Ltd. (2179) Rapporto P/S

Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.

Anno	Rapporto P/S	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/S

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/S	Differenza del rapporto P/S	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	10.95	-	US
Argenx SE ARGX.US	12.19	-	NL
Moderna, Inc. MRNA.US	24.99	-	US
CSL Limited CSL.AX	3.75	-	AU
Lonza Group AG LONN.SW	-	-	CH

Azienda

Rapporto P/S

Differenza del rapporto P/S

Il paese